The local medical community is excited with the arrival of retatrutide, a novel dual GIP and GLP-1 receptor showing remarkable results in clinical trials for addressing obesity. This therapy suggests a https://atozbookmark.com/story21624327/retatrutide-australia-australia-a-potential-hope-for-obesity-treatment